Jeffrey
Turner, MD, Medical Oncologist, Joins Prostate Oncology Specialists in Marina
del Rey, CA.
MARINA
DEL REY, Ca., December 31, 2012 - Prostate Oncology Specialists is pleased to
announce that Jeffrey Turner, MD has joined the prostate cancer specialist
team. Dr. Turner is a board-certified internist and medical oncologist and will
be specializing exclusively in prostate cancer with Mark Scholz and Richard
Lam. Dr. Turner has been specializing in prostate cancer since 2009. He
graduated cum laude from USC. Thereafter, he worked in research at UCLA
studying infectious disease and molecular biology. He earned his medical degree in Canada at
Memorial University of Newfoundland and completed his internal medicine
residency at the University of British Columbia and fellowship in medical
oncology at the Medical University of South Carolina. Dr. Turner has published
several articles on urologic cancers with an emphasis on prostate cancer. He is a sub-investigator of a number of
ongoing prostate cancer clinical trials.
Dr. Mark Scholz, Medical Director of Prostate Oncology
Specialists commented, “Dr. Turner joins
us during a time when the number of new prostate cancer treatments is exploding.
He will add his expertise and knowledge to help patients make informed
decisions. In 2012, we conducted clinical trials with Zytiga and Xtandi, agents
that are now FDA approved. We are
presently evaluating new agents such as Curstersin, XL-184 and Ipilimumab in
combination with Provenge. We are happy
to welcome a talented new member to the team who is familiar with all the many new
treatment options for patients—this also includes Active Surveillance which is
rapidly gaining acceptance as a viable treatment for prostate cancer.”
Active Surveillance remains very popular given the
alternative risk of permanent side-effects from surgery, radiation, or
cryotherapy. Dr. Turner added, “With the
dramatic evolution of today's imaging techniques (including color Doppler
ultrasound and MRI), Active Surveillance is best for men with Gleason 6,
PSA<10, and clinical stage less than or equal to T2a. Due to the fact that
men with Gleason 6 prostate cancer have an incredibly low risk of mortality, Active
Surveillance should remain a strong alternative.”
As skilled leaders in treating prostate cancer, our
medical oncologists use PSA monitoring and color Doppler scanning to accurately
monitor men on Active Surveillance. These techniques can detect early disease
progression in men who may need to pursue treatment intervention.
For more information about Active Surveillance or
Prostate Oncology Specialists - visit: www.keepmyprostate.com or www.prostateoncology.com/activesurveillance
